InvestorsHub Logo
Followers 87
Posts 6692
Boards Moderated 1
Alias Born 09/18/2009

Re: OneDay4488 post# 41026

Sunday, 11/12/2023 3:18:58 PM

Sunday, November 12, 2023 3:18:58 PM

Post# of 42925
It looks to me like the share price in mid-August, when the earnings report was due, was just over one penny. The delayed 2nd quarter 10-Q doesn't seem to be the reason for the then-already low share price.

https://ih.advfn.com/stock-market/USOTC/humanigen-ce-HGEN/historical/more-historical-data

The Baudax auditor identified a non-conformance with recording the purchase price of the Tera-Immune acquisition, which I suspect impacts Durrant's ability to adequately reflect that transaction on our 2nd quarter 10-Q.

If you don't want to recognize any other reason for the delay, such as in regards to establishing a strategic advantage for the company, then you should at least consider that Durrant shared the Baudax auditor's opinion, and needs to ensure that he would be in compliance with how he reflects our acquisition of Baudax shares on the last day of Q2.